- Home
- HCI vs ZYME Comparison
HCI vs ZYME Comparison
Compare HCI & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCI | ZYME |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2008 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HCI | ZYME |
|---|---|---|
| Price | $174.69 | $27.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $230.00 | $38.90 |
| AVG Volume (30 Days) | 104.2K | ★ 512.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 155.57 | 33.33 |
| EPS | ★ 11.05 | N/A |
| Revenue | ★ $900,946,000.00 | $105,965,000.00 |
| Revenue This Year | $11.44 | $183.10 |
| Revenue Next Year | $7.67 | N/A |
| P/E Ratio | $15.87 | ★ N/A |
| Revenue Growth | 20.12 | ★ 38.87 |
| 52 Week Low | $144.75 | $16.00 |
| 52 Week High | $210.50 | $31.34 |
Technical Indicators
Market Signals| Indicator | HCI | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 50.68 |
| Support Level | $172.50 | $22.10 |
| Resistance Level | $182.10 | $27.30 |
| Average True Range (ATR) | 4.01 | 1.03 |
| MACD | -1.50 | -0.15 |
| Stochastic Oscillator | 19.41 | 59.88 |
Price Performance
Historical ComparisonAbout HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.